Kempower Launches Partnership With Gilbarco Veeder-Root to Offer EV Charging Solutions
7.10.2021 13:02:00 EEST | Business Wire | Press release
Kempower, a leading e-mobility charging technology provider, has announced a partnership with Gilbarco Veeder-Root (GVR), the global leader in technology solutions for the retail fueling and convenience market. GVR will offer Kempower’s EV chargers as part of its EVerse offering, which also includes network management software, installation and maintenance services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211007005493/en/
Kempower, a leading e-mobility charging technology provider, has announced a partnership with Gilbarco Veeder-Root (GVR), the global leader in technology solutions for the retail fueling and convenience market. GVR will offer Kempower’s EV chargers as part of its EVerse offering, which also includes network management software, installation and maintenance services. (Photo: Business Wire)
Kempower’s DC fast charging solutions are built to scale as the number of EVs on the road continues to rise. The company’s high-quality charging solutions are suitable for all types of EVs, including passenger cars, buses, off-highway vehicles, commercial service fleets and marine vessels.
“We are extremely happy to launch this cooperation with GVR. Our modular approach means that standardized building blocks can be used across our entire product range, enabling the creation of various types of EV chargers and charging systems. Additionally, our technology is scalable, so our customers can make smaller initial investments and add additional power modules later as their business grows,” commented Kempower’s CEO Tomi Ristimäki.
With a strong heritage of providing industry-leading integrated software, hardware and services for the retail fueling and convenience market, GVR offers broad market reach, proven reliability and expert industry insights on how customers are evolving their workflows to address the growing complexity shaping the e-mobility infrastructure landscape. The company specializes in creating end-to-end EV charging infrastructure solutions to improve the consumer experience and increase productivity for operators.
“Our native IoT chargers can be updated remotely and in real-time, reassuring our customers that their chosen solutions are future-proof and cloud-connected at all times. The modularity of the products also ensures that they have a small footprint, allowing GVR’s customers to make use of limited space in densely populated areas,” Ristimäki added.
Press images:
https://kempower.com/information-center/download-center/
About Kempower
Kempower designs and manufactures DC fast charging solutions for electric vehicles and machines. We’re a team of electric vehicle enthusiasts with a deep understanding of the charging market and a hands-on mentality. Our product development and production are rooted in Finland, with over 90% of our materials and components sourced locally. We focus on all areas of transportation, from personal cars and commercial vehicles to mining equipment, boats and motorsports. With 70 years of experience in perfecting power sources, we set the bar in engineering and user-experience design.
About Gilbarco Veeder-Root
Gilbarco Veeder-Root (GVR) is the global leader for technology solutions for retail fueling and convenience market. For over 150 years, GVR has been keeping the world moving, earning the trust of its customers by providing long-term partnership, uncompromising support, and proven reliability. Major product lines include point-of-sale software, payment systems, EV charging solutions, fuel dispensers and tank gauges and fleet management solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005493/en/
Contact information
Tomi Ristimäki
CEO
Kempower
tomi.ristimaki@kempower.com
+358 44 289 9815
Paula Savonen
Communications Director
Kempower
paula.savonen@kempower.com
+358 400 343 851
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom